AbCellera Biologics Inc. Stock

Equities

ABCL

CA00288U1066

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-10 pm EDT 5-day change 1st Jan Change
3.83 USD -3.04% Intraday chart for AbCellera Biologics Inc. -4.96% -32.92%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 40.4M Sales 2025 * 59.62M Capitalization 1.13B
Net income 2024 * -177M Net income 2025 * -221M EV / Sales 2024 * 24.9 x
Net cash position 2024 * 120M Net cash position 2025 * 2M EV / Sales 2025 * 18.8 x
P/E ratio 2024 *
-6.69 x
P/E ratio 2025 *
-6.11 x
Employees 586
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.02%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.04%
1 week-4.96%
Current month+1.32%
1 month-14.13%
3 months-25.05%
6 months-5.20%
Current year-32.92%
More quotes
1 week
3.78
Extreme 3.78
4.28
1 month
3.62
Extreme 3.62
4.42
Current year
3.62
Extreme 3.62
6.06
1 year
3.62
Extreme 3.62
8.05
3 years
3.62
Extreme 3.62
36.05
5 years
3.62
Extreme 3.62
71.91
10 years
3.62
Extreme 3.62
71.91
More quotes
Managers TitleAgeSince
Founder 39 12-11-07
Founder - 12-11-07
Chief Executive Officer 49 12-11-07
Members of the board TitleAgeSince
Director/Board Member 59 20-10-31
Director/Board Member 72 19-09-30
Director/Board Member 63 21-12-06
More insiders
Date Price Change Volume
24-05-10 3.83 -3.04% 1,193,867
24-05-09 3.95 +2.86% 1,021,046
24-05-08 3.84 -4.95% 1,333,528
24-05-07 4.04 -1.70% 2,175,538
24-05-06 4.11 +1.99% 1,823,908

Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT

More quotes
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.83 USD
Average target price
12.71 USD
Spread / Average Target
+231.97%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW